Company profile
DYNE THERAPEUTICS, INC.
NASDAQ:DYNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZELECIMENT BASIVARSEN | phase3 | — | 2 | active |
| ZELECIMENT ROSTUDIRSEN | phase3 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07486934 | phase3 | recruiting | 2026-05-14 | 2028-07-01 | Dyne Therapeutics | Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 |
| NCT07608432 | phase3 | recruiting | 2026-06-01 | 2030-12-01 | Dyne Therapeutics | Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) |
| NCT05481879 | phase1_2 | active_not_recruiting | 2022-09-05 | 2029-07-01 | Dyne Therapeutics | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 |
| NCT05524883 | phase1_2 | active_not_recruiting | 2022-08-12 | 2031-09-01 | Dyne Therapeutics | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping |
FDA applications (0)
No records yet.